Back to search

Article

Adenomatous Polyposis Coli Loss Controls Cell Cycle Regulators and Response to Paclitaxel

2020-11-01

Abstract excerpt

Adenomatous Polyposis Coli (APC) is lost in approximately 70% of sporadic breast cancers, with an inclination towards triple negative breast cancer (TNBC). TNBC is treated with traditional chemotherapy, such as paclitaxel (PTX); however, tumors often develop drug resistance. We previously created APC knockdown cells (APC shRNA1) using the human TNBC cells, MDA-MB-157, and showed that APC loss induces PTX resistanc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
626fd069-0d3e-5def-9d8a-7d54d6c19bcb
DOI
10.1101/2020.10.31.362608
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Adenomatous Polyposis Coli Loss Controls Cell Cycle Regulators and Response to PaclitaxelDOI 10.1101/2020.10.31.362608
Select a neighboring publication to make it the new centre.